Search results
Results from the WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
APON/BPON, EPON and GPON have been widely deployed. In November 2014, EPON had approximately 40 million deployed ports and ranks first in deployments. [47] As of 2015, GPON had a smaller market share, but is anticipated to reach $10.5 billion US dollars by 2020. [48] For TDM-PON, a passive optical splitter is used in the optical distribution ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Treatment of generalized pustular psoriasis (GPP) in people aged twelve years of age and older and weighing at least 40 kg [2] Tarlatamab: Treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy [2] Tirzepatide: Eli Lilly
The GPON OMCI recommendation G.984.4 draws on G.983.2, which defines the BPON management model. However, G.984.4 removed all references to ATM. G.988 is a stand-alone OMCI recommendation and supersedes G.984.4 except for GPON specifics that are not defined in G.988. Future work on the PON management model is expected to appear only in the GPON ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
Alberts DS, Golde DW (November 1974). "DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy".Cancer Res.34 (11): 2911– 4. PMID 4424360. ...
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.